Eris Lifesciences Limited
DSP Mutual Fund disclosed a 1.05% stake in Eris Lifesciences Limited, holding 14,55,856 shares, up from under 1% in the prior filing.
A pharmaceutical manufacturer and marketer, ERIS Lifesciences produces branded and generic drugs across multiple therapeutic areas including cardiovascular, gastroenterology, and anti-infective segments. The company operates manufacturing facilities and distributes medications through established distribution networks to serve both domestic and international markets. It focuses on developing and delivering cost-effective pharmaceutical formulations for diverse patient populations.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.